{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape#webpage",
"url": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape",
"name": "Driving a biotech’s early phase development in a competitive rare disease clinical trial landscape",
"description": "Explore this Fortrea Case Study demonstrating how a proactive, site-centric strategy, early engagement, and scientific leadership accelerated Phase Ib recruitment for a biotech sponsor developing an immunomodulating therapy for chronic graft-versus-host disease (cGVHD). Facing a competitive rare disease clinical trial landscape, limited patient availability, reduced sponsor visibility in the EU, and recruitment challenges following study consolidation, Fortrea focused on high-potential hematopoietic stem cell transplantation (HSCT) centers, strengthened investigator engagement through scientific leadership, and maintained transparent communication with participating sites. This targeted approach exceeded recruitment expectations, reduced enrollment timelines by 50%, strengthened sponsor-site collaboration, increased sponsor visibility, and established a solid foundation for Phase II development, demonstrating the value of proactive site engagement in early phase rare disease clinical trials."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Driving a biotech’s early phase development in a competitive rare disease clinical trial landscape",
"item": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/driving-biotechs-early-phase-development-competitive-rare-disease-clinical-trial-landscape#webpage"
},
"headline": "Accelerating Phase Ib Recruitment in a Rare Disease Clinical Trial | Fortrea Case Study",
"description": "Explore this Fortrea Case Study demonstrating how a proactive, site-centric strategy, early engagement, and scientific leadership accelerated Phase Ib recruitment for a biotech sponsor developing an immunomodulating therapy for chronic graft-versus-host disease (cGVHD). Facing a competitive rare disease clinical trial landscape, limited patient availability, reduced sponsor visibility in the EU, and recruitment challenges following study consolidation, Fortrea focused on high-potential hematopoietic stem cell transplantation (HSCT) centers, strengthened investigator engagement through scientific leadership, and maintained transparent communication with participating sites. This targeted approach exceeded recruitment expectations, reduced enrollment timelines by 50%, strengthened sponsor-site collaboration, increased sponsor visibility, and established a solid foundation for Phase II development, demonstrating the value of proactive site engagement in early phase rare disease clinical trials.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-05-11",
"dateModified": "2026-05-11",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-05/early-phase-biotech-rare-disease-clinical-trial-case-study.pdf",
"encodingFormat": "application/pdf"
}
}
]
}